Search Results 8231-8240 of 42436 for oral

  1. Tongue cancer - Doctors and departments - Mayo Clinic

    Investigating tumor growth factors for oral cancer. Evaluating new methods of use for chemotherapy. Evaluating new radiation therapy regimens. Investigating ...

  2. Jill Adamski, M.D., Ph.D. - Doctors and Medical Staff - Mayo Clinic

    1st Place - Oral Presentation5th Annual MSTP Scientific Retreat, University of Alabama at Birmingham. 2003. Training Program in Rheumatic Diseases Research ...

  3. Escalating Dose Study in Subjects with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia - Mayo Clinic

    Eastern Cooperative Oncology Group performance status of ≤ 2 and a life expectancy of at least 3 months. Ability to swallow oral capsules without difficulty ...

  4. A Study of JNJ‐68284528 Out‐of‐Specification (OOS) for Commercial Release in Patients with Multiple Myeloma - Mayo Clinic

    A woman using oral contraceptives must use an additional contraceptive method. A woman must be: Not of childbearing potential;; Of childbearing potential ...

  5. Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab - Mayo Clinic

    Participation eligibility · Pneumonitis that requires oral or IV steroids; · Or known cases of hepatobiliary diseases (e.g., primary biliary cholangitis, primary ...

  6. Type 1 diabetes - Diagnosis and treatment - Mayo Clinic

    Diagnosis. Diagnostic tests include: Glycated hemoglobin (A1C) test. This blood test shows your average blood sugar level for the past 2 to 3 months.

  7. Cancer diagnosis: 11 tips for coping - Mayo Clinic

    Ask your healthcare professional what may change. Medicines may make you lose your hair. Advice from experts about clothing, makeup, wigs and hairpieces may ...

  8. Olanzapine For The Treatment Of Chronic Nausea And/or Vomiting In Advanced Cancer Patients - Mayo Clinic

    Inability to swallow oral formulations of the agent(s). Tube feeding or nasogastric tube. Eligibility last updated 10/27/21. Questions regarding updates ...

  9. Rivet PVS Therapy in Group 2C - Mayo Clinic

    ≥ 1 HF hospitalization, or healthcare facility with IV diuretics or intensification of oral diuresis for HF within 12 months, or NT-pro BNP value > 400 pg/mL ...

  10. Venetoclax-Dexamethasone In Relapsed And/or Refractory T(11;14) Amyloidosis - Mayo Clinic

    Known GI disease or GI procedure that could interfere with oral absorption (including difficulty swallowing) - New York Heart Association (NYHA) Class III ...